YAG
TRIB

Yorkville Advisors Global’s Trinity Biotech TRIB Stock Holding History

Yorkville Advisors Global’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,500
Closed -$122K – 44
2026
Q1 		$122K Buy
+7,500
New +$166K 0.08% 34

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Yorkville Advisors Global's TRIB Position: Q2 2026 in Review

Yorkville Advisors Global sold out of Trinity Biotech (TRIB) in Q2 2026, closing a stake of 7,500 shares — an estimated $122K sold.

Yorkville Advisors Global first reported a position in TRIB in Q1 2026 and held it in 1 quarter. The position peaked at $122K in Q1 2026. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

  • Yorkville Advisors Global reported no remaining Trinity Biotech position as of Q2 2026 after selling out during the quarter.
  • Yorkville Advisors Global sold 7,500 Trinity Biotech shares in Q2 2026, an estimated $122K.
  • Yorkville Advisors Global first reported a position in Trinity Biotech in Q1 2026 and held it in 1 quarter.
  • Yorkville Advisors Global's Trinity Biotech position peaked at $122K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on Yorkville Advisors Global's 13F filing for Q2 2026, filed 6 Aug 2026.